The need for a clinical case definition in test-negative design studies estimating vaccine effectiveness.


Journal

NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863

Informations de publication

Date de publication:
12 Aug 2023
Historique:
received: 13 03 2023
accepted: 01 08 2023
medline: 13 8 2023
pubmed: 13 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

Test negative studies have been used extensively for the estimation of COVID-19 vaccine effectiveness (VE). Such studies are able to estimate VE against medically-attended illness under certain assumptions. Selection bias may be present if the probability of participation is associated with vaccination or COVID-19, but this can be mitigated through use of a clinical case definition to screen patients for eligibility, which increases the likelihood that cases and non-cases come from the same source population. We examined the extent to which this type of bias could harm COVID-19 VE through systematic review and simulation. A systematic review of test-negative studies was re-analysed to identify studies ignoring the need for clinical criteria. Studies using a clinical case definition had a lower pooled VE estimate compared with studies that did not. Simulations varied the probability of selection by case and vaccination status. Positive bias away from the null (i.e., inflated VE consistent with the systematic review) was observed when there was a higher proportion of healthy, vaccinated non-cases, which may occur if a dataset contains many results from asymptomatic screening in settings where vaccination coverage is high. We provide an html tool for researchers to explore site-specific sources of selection bias in their own studies. We recommend all groups consider the potential for selection bias in their vaccine effectiveness studies, particularly when using administrative data.

Identifiants

pubmed: 37573443
doi: 10.1038/s41541-023-00716-9
pii: 10.1038/s41541-023-00716-9
pmc: PMC10423262
doi:

Types de publication

Journal Article

Langues

eng

Pagination

118

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI141534
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM139926
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2023. Springer Nature Limited.

Références

Tsang, T. K. et al. Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative study: a systematic review and meta-analysis. medRxiv, 2022.2011.2003.22281925, https://doi.org/10.1101/2022.11.03.22281925 (2022).
Chua, H. et al. The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology 31, 43–64 (2020).
doi: 10.1097/EDE.0000000000001116 pubmed: 31609860 pmcid: 6888869
Sullivan, S. G. & Cowling, B. J. "Crude vaccine effectiveness" is a misleading term in test-negative studies of influenza vaccine effectiveness. Epidemiology 26, e60 (2015).
doi: 10.1097/EDE.0000000000000343 pubmed: 26133018 pmcid: 4522193
Sullivan, S. G., Feng, S. & Cowling, B. J. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev. Vaccines 13, 1571–1591 (2014).
doi: 10.1586/14760584.2014.966695 pubmed: 25348015 pmcid: 4277796
Sullivan, S. G., Tchetgen Tchetgen, E. J. & Cowling, B. J. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am. J. Epidemiol. 184, 345–353 (2016).
doi: 10.1093/aje/kww064 pubmed: 27587721 pmcid: 5013887
Ainslie, K. E. C., Haber, M. & Orenstein, W. A. Bias of influenza vaccine effectiveness estimates from test-negative studies conducted during an influenza pandemic. Vaccine 37, 1987–1993 (2019).
doi: 10.1016/j.vaccine.2019.02.036 pubmed: 30833155 pmcid: 6449847
Foppa, I. M., Haber, M., Ferdinands, J. M. & Shay, D. K. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 31, 3104–3109 (2013).
doi: 10.1016/j.vaccine.2013.04.026 pubmed: 23624093
Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31, 2165–2168 (2013).
doi: 10.1016/j.vaccine.2013.02.053 pubmed: 23499601
Ainslie, K. E. C., Haber, M. & Orenstein, W. A. Challenges in estimating influenza vaccine effectiveness. Expert Rev. Vaccines 18, 615–628 (2019).
doi: 10.1080/14760584.2019.1622419 pubmed: 31116070 pmcid: 6594904
Lewnard, J. A. et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines. Epidemiology 32, 508–517 (2021).
doi: 10.1097/EDE.0000000000001366 pubmed: 34001753 pmcid: 8168935
Thompson, M. G. et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 139–145 (2022).
doi: 10.15585/mmwr.mm7104e3 pubmed: 35085224 pmcid: 9351525
Stensrud, M. J. Identification of vaccine effects when exposure status is unknown. Epidemiology 34, 216–224 (2023).
doi: 10.1097/EDE.0000000000001573 pubmed: 36696229 pmcid: 9891279
Infante-Rivard, C. & Cusson, A. Reflection on modern methods: selection bias-a review of recent developments. Int. J. Epidemiol. 47, 1714–1722 (2018).
doi: 10.1093/ije/dyy138 pubmed: 29982600
Chadeau-Hyam, M. et al. SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. Lancet Respir. Med. 10, 355–366 (2022).
doi: 10.1016/S2213-2600(21)00542-7 pubmed: 35085490 pmcid: 8786320
Halloran, M. E., Longini, I. M. Jr. & Struchiner, C. J. Design and interpretation of vaccine field studies. Epidemiol. Rev. 21, 73–88 (1999).
doi: 10.1093/oxfordjournals.epirev.a017990 pubmed: 10520474
Geneletti, S., Mason, A. & Best, N. Adjusting for selection effects in epidemiologic studies: why sensitivity analysis is the only "solution". Epidemiology 22, 36–39 (2011).
doi: 10.1097/EDE.0b013e3182003276 pubmed: 21150353
Geneletti, S., Richardson, S. & Best, N. Adjusting for selection bias in retrospective, case-control studies. Biostatistics 10, 17–31 (2009).
doi: 10.1093/biostatistics/kxn010 pubmed: 18482997
Greenland, S. Basic methods for sensitivity analysis of biases. Int. J. Epidemiol. 25, 1107–1116 (1996).
doi: 10.1093/ije/25.6.1107 pubmed: 9027513
Westreich, D. Berkson’s bias, selection bias, and missing data. Epidemiology 23, 159–164 (2012).
doi: 10.1097/EDE.0b013e31823b6296 pubmed: 22081062 pmcid: 3237868

Auteurs

Sheena G Sullivan (SG)

WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, and Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. sheena.sullivan@influenzacentre.org.
Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA. sheena.sullivan@influenzacentre.org.

Arseniy Khvorov (A)

WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, and Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.

Xiaotong Huang (X)

WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Can Wang (C)

WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Kylie E C Ainslie (KEC)

WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.

Joshua Nealon (J)

WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Bingyi Yang (B)

WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Benjamin J Cowling (BJ)

WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China.

Tim K Tsang (TK)

WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Classifications MeSH